Skip to content
Markets News
Stocks1 min read

Regeneron Reports Longer-Term Libtayo Results in High-Risk Skin Cancer

Makkler Newsroom
October 25, 2026 · Based on reporting by GlobeNewswire

Nearly four years of follow-up showed a larger reported overall-survival benefit, while exploratory analyses found disease-free survival gains across baseline MRD groups.

Key takeaways

  • At 44 months’ median follow-up, Regeneron reported a 37% lower risk of death with Libtayo versus placebo.
  • Exploratory analyses found improved disease-free survival with Libtayo in both baseline MRD-negative and MRD-positive patients.

Regeneron reported longer-term results from its Phase 3 C-POST trial, finding a 37% reduction in the risk of death with adjuvant Libtayo versus placebo after a median 44 months of follow-up. Overall survival was a secondary endpoint; the hazard ratio was 0.63, with a 95% confidence interval of 0.36 to 1.11.

The trial studied patients with high-risk cutaneous squamous cell carcinoma after surgery and radiation. Among placebo patients whose cancer recurred, 61 of 69, or 88%, later received Libtayo, according to Regeneron.

An exploratory analysis found improved disease-free survival with Libtayo among patients who were minimal residual disease-negative at baseline (HR 0.45) and those who were MRD-positive (HR 0.24). The data were presented at the 2026 European Society for Medical Oncology meeting.

Topics
REGNLibtayo

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.